Namal Nawana

Jan 12, 2018

Hologic elected Namal Nawana to its board of directors. Nawana was formerly the chief executive officer of Alere, which was acquired by Abbott Laboratories in Oct. 2017.  Before joining Alere, he spent 15 years at Johnson & Johnson in various leadership roles, most recently as the worldwide president of DePuy Synthes Spine.

More Like This

Nov 09, 2018

Anne Jones

Anne Jones has been appointed as CEO of Genomics Medicine Ireland. She joins the company from Danaher, where she was vice president and general manager for the Pall Corporations Lab, Food, and Beverage business. Prior to that, she was vice president of strategy and business development at Agilent Technologies. She also held various marketing and R&D roles at Amersham Biosciences in the UK and at GE Healthcare Life Sciences in the UK and the US. Jones holds a undergraduate degree in microbiology and molecular biology from the National University of Ireland and a PhD from Cancer Research UK.

Nov 08, 2018

Jeffrey Jeddeloh, Stephen Macevicz, Christine Peponnet

Jeffrey Jeddeloh, Stephen Macevicz, and Christine Peponnet have joined the new US subsidiary of French DNA synthesis firm DNA Script.  

Jeddeloh was appointed as vice president of business development and commercial strategy. Most recently, he was director of business development for Roche Molecular Solutions. Prior to that, he was R&D director at Orion Genomics. He holds a PhD from Washington University and an MBA from the University of Wisconsin.

Macevicz has become the firm's vice president of intellectual property. Previously, he was vice president of IP at Sequenta and at Ion Torrent, as well as senior IP attorney at Becton Dickinson. He holds a PhD in biophysics and a JD from the University of California, Berkeley.

Peponnet has joined the company as vice president of technology development. Most recently, she was head of the biosystems group at CEA (Center for Atomic Energy), where she helped to develop a microfluidic technology that was licensed to Advanced Liquid Logic, which was later acquired by Illumina. Prior to that, she worked at Caliper Technologies, and before that, she was head of genotyping R&D at Genset.

Nov 08, 2018

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

Nov 08, 2018

Scott Tomlins

Strata Oncology has appointed Scott Tomlins as the firm's chief medical officer. Prior to Strata, Tomlins was an associate professor of pathology at the University of Michigan. Tomlins will maintain an adjunct faculty position at the university's medical school. Tomlins' academic research has focused on applying high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. 

Nov 07, 2018

Scott Nicholson, Cory Dunn

Biocept has appointed Scott Nicholson as its Vice President of Sales in the US and Cory Dunn as its Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was vice president of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.

Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suit of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.

In connection with the hirings, Biocept said it granted each individual an inducement stock option award to purchase 24,200 shares of Biocept common stock, with an exercise price per share equal to the closing price of Biocept's common stock on October 31, 2018.

Nov 06, 2018

Marc Stapley

Marc Stapley plans to leave Illumina, effective Jan 1., 2019. Stapley is currently executive vice president of strategy and corporate development at Illumina, where he is responsible for corporate strategy, corporate and business development, and infrastructure. He joined Illumina in 2012 and has held multiple roles with the firm, including as chief financial officer and chief administrative officer. Prior to joining Illumina, he was senior vice president of finance at Pfizer.

Nov 05, 2018

Oved Amitay

Centogene has appointed Oved Amitay its chief business officer. He has almost 30 years of commercial and development experience with a focus on orphan drugs for patients with rare genetic diseases. Amitay joins Centogene from Arrett Neuroscience where he was president and COO. Prior to that he was VP, head of commercial at Alnylam Pharmaceuticals. 

Nov 02, 2018

Peter Collins

Peter Collins has stepped down as chief business officer and director of Premaitha Health, effective November 1. Previously, he was vice president and head of diagnostics at GlaxoSmithKline.

Nov 01, 2018

Susan Rolih

Meridian Bioscience said this week that Susan Rolih, executive VP of global regulatory and quality systems, will retire on Nov. 30, 2018. She worked for the firm for 18 years and is expected to serve as a consultant on an as-requested basis with matters related to FDA remediation efforts at the firm's Magellan Diagnostics business, among other matters.

Nov 01, 2018

Jan Groen

Liquid biopsy firm Angle has appointed Jan Groen as a non-executive director, effective Nov. 1. He is currently president and CEO of MDxHealth. Prior to joining that firm, he was president of US operations and global chief operating officer at Agendia. Groen is also a non-executive board member of SPL Medical. 

Nov 01, 2018

Jason Gammack

Gene editing technology company Inscripta has appointed Jason Gammack as its first chief commercial officer. Gammack will design and oversee Inscripta's sales, marketing, business development, and customer support operations. He most recently served as vice president of Qiagen's life science business, where he led the development of the life science portfolio and go-to-market strategy. Prior to Qiagen, Gammack developed commercialization growth strategies at bioinformatics company Ingenuity Systems, which was acquired by Qiagen in 2013, and has also held senior leadership roles at Sigma-Aldrich, Life Technologies, Affymetrix, and Promega.  

Nov 01, 2018

Adam Margolin, Eric Schadt

Mount Sinai’s School of Medicine has hired Adam Margolin, former director of computational biology at Oregon Health & Science University, to lead a new initiative on data science and precision medicine. Margolin will take on the positions previously held by Eric Schadt, who was hired in 2011 to lead Mount Sinai’s programs in data science and genomics. Schadt will continue at Mount Sinai in his role as dean for precision medicine at the school of medicine. He will also remain CEO of Mount Sinai diagnostics spinout Sema4, which provides noninvasive prenatal screening, genetic carrier screening, newborn genetic disease testing, and tumor genetic testing to personalize cancer treatments.

Oct 31, 2018

Maureen Cronin

HTG Molecular Diagnostics has appointed Maureen Cronin as its CSO and senior vice president, effective Nov. 16. Cronin served as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior vice president of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Oct 31, 2018

Laura Clague

Laura Clague has been appointed to the board of directors of Fluidigm. She is the CFO of Retrophin. Previously, she was the CFO of the San Diego and Ohio operations of Amylin Pharmaceuticals, following the company's acquisition by Bristol-Myers Squibb. Prior to that, she was vice president, corporate controller, and principal accounting officer at Amylin, as well as CFO of Amylin's collaboration with Eli Lilly and Company. Clague holds a BS in business administration from Menlo College.

Oct 26, 2018

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its chief commercial officer. Hanna previous served as president and chief operating officer at Origin. Prior to Origin, she held multiple positions over an eight-year period at J&J, with her most recent position as VP of global strategic marketing for Vision Care.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.